A novel recombinant human plasminogen activator: Efficient expression and hereditary stability in transgenic goats and in vitro thrombolytic bioactivity in the milk of transgenic goats
10.1371/journal.pone.0201788 · doi-reference
Expression and large-scale production of the biochemically active human tissue-plasminogen activator in hairy roots of Oriental melon (Cucumis melo)
10.1016/j.jbiosc.2011.09.008 · doi-reference
High-level expression of a novel recombinant human plasminogen activator (rhPA) in the milk of transgenic rabbits and its thrombolytic bioactivity in vitro
10.1007/s11033-016-4020-0 · doi-reference
Expression of active chimeric-tissue plasminogen activator in tobacco hairy roots, identification of a DNA aptamer and purification by aptamer functionalized-MWCNTs chromatography
10.1016/j.pep.2016.02.004 · doi-reference
Expression and characterization of human tissue-plasminogen activator in transgenic tobacco plants
10.1007/s11105-008-0075-y · doi-reference
A comparative investigation on different refolding strategies of recombinant human tissue-type plasminogen activator derivative
10.1007/s10529-006-0001-z · doi-reference
Development of a two-step refolding method for reteplase, a rich disulfide-bonded protein
10.1016/j.procbio.2018.05.006 · doi-reference
Purification and efficient refolding process for recombinant tissue-type plasminogen activator derivative (reteplase) using glycerol and Tranexamic acid
10.1016/j.procbio.2016.11.020 · doi-reference
Impact of oxygen supply on rtPA expression in Escherichia coli BL21 (DE3): ammonia effects
10.1007/s00253-008-1756-z · doi-reference
Auto-induction for high level production of biologically active reteplase in Escherichia coli
10.1016/j.pep.2018.05.008 · doi-reference
High-level expression of a biologically active staphylokinase in Pichia pastoris
10.1080/10826068.2016.1252924 · doi-reference
Optimized gene synthesis, expression and purification of active salivary plasminogen activator α2 (DSPAα2) of desmodus rotundus in Pichia pastoris
10.1016/j.pep.2007.09.001 · doi-reference
10.1007/s12010-010-8979-z
10.1007/s12010-010-8979-z · doi-reference
Co-expression of disulfide oxidoreductases DsbA/DsbC markedly enhanced soluble and functional expression of reteplase in Escherichia coli
10.1016/j.jbiotec.2014.10.028 · doi-reference
10.1002/jnr.24112
10.1002/jnr.24112 · doi-reference
10.1111/jth.13033
10.1111/jth.13033 · doi-reference
10.1371/journal.pone.0150315
10.1371/journal.pone.0150315 · doi-reference
Thrombolytic therapy targeting alpha 2-antiplasmin
10.1161/circulationaha.117.026884 · doi-reference
Releasing the brakes on the fibrinolytic system in pulmonary emboli unique effects of plasminogen activation and alpha 2-antiplasmin inactivation
10.1161/circulationaha.116.024421 · doi-reference
Inhibition of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 reduces ischemic brain damage in mice
10.1161/strokeaha.116.014091 · doi-reference
Innovative thrombolytic strategy using a heterodimer diabody against TAFI and PAI-1 in mouse models of thrombosis and stroke
10.1182/blood-2014-07-588319 · doi-reference
novel small molecule inhibitors of activated thrombin activatable fibrinolysis inhibitor (tafia) from natural product anabaenopeptin
10.1021/jm501840b · doi-reference
Isolation, co-crystallization and structure-based characterization of anabaenopeptins as highly potent inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa)
10.1038/srep32958 · doi-reference
Thrombin activatable fibrinolysis inhibitor: a putative target to enhance fibrinolysis
10.1055/s-0033-1334488 · doi-reference
Development of a novel RANKL-based peptide, microglial healing peptide1-AcN (MHP1-AcN), for treatment of ischemic stroke
10.1038/s41598-018-35898-z · doi-reference
10.5551/jat.rv16006
10.5551/jat.rv16006 · doi-reference
LDL receptor blockade reduces mortality in a mouse model of ischaemic stroke without improving tissue-type plasminogen activator-induced brain haemorrhage: towards pre-clinical simulation of symptomatic ICH
10.1186/s12987-017-0081-2 · doi-reference
Selective inhibition of brain endothelial Rhokinase-2 provides optimal protection of an in vitro blood-brain barrier from tissue-type plasminogen activator and plasmin
10.1371/journal.pone.0177332 · doi-reference
10.3390/ijms19061635
10.3390/ijms19061635 · doi-reference
Uric acid enhances alteplase-mediated thrombolysis as an antioxidant
10.1038/s41598-018-34220-1 · doi-reference
Preclinical toxicological assessment of a novel monoclonal antibody targeting human platelet-derived growth factor CC (PDGF-CC) in PDGF-CChum mice
10.1371/journal.pone.0200649 · doi-reference
Tissue-type plasminogen activator-binding RNA aptamers inhibiting low-density lipoprotein receptor family-mediated internalisation
10.1160/th14-08-0686 · doi-reference
10.1021/jacs.8b10166
10.1021/jacs.8b10166 · doi-reference
Recent advances in the therapeutic and diagnostic use of liposomes and carbon nanomaterials in ischemic stroke
10.3389/fnins.2018.00453 · doi-reference
10.1021/acs.molpharmaceut.7b00559
10.1021/acs.molpharmaceut.7b00559 · doi-reference
10.1039/c6tb01349j
10.1039/c6tb01349j · doi-reference
10.1016/j.jconrel.2016.02.019
10.1016/j.jconrel.2016.02.019 · doi-reference
10.1080/17425247.2018.1384464
10.1080/17425247.2018.1384464 · doi-reference
10.1126/science.1217815
10.1126/science.1217815 · doi-reference
Evaluation of the effects of a new series of SMTPs in the acetic acid-induced embolic cerebral infarct mouse model
10.1016/j.ejphar.2017.10.055 · doi-reference
